On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted favorably on six of seven research peptides, including BPC-157, TB-500, Semax and MOTS-c. Coverage since then has called it everything from an approval to a ban. It was neither. Here is what the committee actually did, what FDA staff had recommended going in, and what changed on October 28, 2026, when HHS announced a temporary policy for six of these peptides.
What Changed on October 28, 2026
Three months after the vote, the picture moved. On October 28, 2026, HHS announced an interim enforcement discretion policy for six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. These are the same six the committee voted for in July. DSIP (emideltide), which the committee voted down, is not part of it.
Under the policy, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound one of these six peptides with a valid patient-specific prescription, as long as every condition is met. It is temporary. It lasts while FDA decides through rulemaking whether to add each peptide to the list of bulk substances that state-licensed pharmacies can use in compounding, and it ends for a peptide once a final rule addresses it. It is not FDA approval, and HHS says it can revisit the policy, in whole or in part, if a safety signal or product quality issue arises. The full text is in the Federal Register notice (FR Doc 2026-22192).
The main conditions:
- Single ingredient only. Each compounded product can contain one of the six peptides. Blends, such as BPC-157 and TB-500 in one vial, are outside the policy.
- Verified supply. The bulk peptide must come from an FDA-registered facility, with a certificate of analysis testing identity, purity, potency, endotoxin, heavy metals, microbial contamination and impurities. The original manufacturer must be FDA-registered and follow current good manufacturing practice.
- Specific routes only, listed in the table below. Oral forms also need documentation of adequate human oral bioavailability.
- Reporting and labeling. Compounders report products compounded, serious adverse events and quality issues to FDA MedWatch and the states, and the label must read "This is a compounded drug product. Not for resale."
- Everything else still applies, including a valid prescription for an individual patient and no insanitary conditions. The only device that can be packaged with the product is a syringe with FDA 510(k) clearance.
| Peptide | Routes covered by the HHS policy |
|---|---|
| BPC-157 | Subcutaneous, intramuscular, oral, topical |
| TB-500 | Subcutaneous or intramuscular injection |
| MOTS-c | Subcutaneous or intramuscular injection |
| Epitalon | Subcutaneous or intramuscular injection, in intermittent courses |
| Semax | Intranasal only |
| KPV | Topical and oral only (not injectable) |
So the July vote still matters. It is the recommendation FDA is weighing in rulemaking. What changed is that, while that rulemaking runs, HHS has said it will not pursue enforcement against compounders that follow these conditions.
What Happened on July 23 and 24, 2026
The FDA's Pharmacy Compounding Advisory Committee, usually shortened to PCAC, met over two days to review seven peptides nominated for possible addition to the list of bulk substances that state-licensed pharmacies can use in compounding. That list defines which bulk drug substances licensed compounding pharmacies may use when preparing medications for individual patients under the federal compounding rules for state-licensed pharmacies.
The seven peptides under review were BPC-157, KPV, TB-500, MOTS-c, emideltide (also known as DSIP, or delta sleep-inducing peptide), epitalon and Semax.
The committee voted favorably to recommend adding six of them: BPC-157, TB-500, KPV, MOTS-c, Semax and epitalon. Emideltide, the DSIP entry, was not recommended.
That is where most coverage stopped. The rest of this article covers the part that mattered more at the time, and still shapes what happens next.
What a PCAC Vote Actually Is, and What It Is Not
PCAC is an advisory committee. Advisory committees exist to give the FDA outside expert input on scientific and policy questions. Members are external experts convened to discuss the evidence in public, ask questions of agency reviewers, and register an opinion by vote. They are not FDA decision-makers, and they do not write regulation.
Three things follow directly from that:
- A favorable PCAC vote is a recommendation, not a decision.
- PCAC recommendations are advisory and non-binding. The FDA may accept, modify, or decline them.
- Nothing an advisory committee votes on takes legal effect on the day of the vote.
The committee's charter, membership and meeting materials are published on the FDA's Pharmacy Compounding Advisory Committee page, and the current bulks framework is documented on the FDA's page on bulk drug substances used in compounding. The October 28, 2026 HHS policy is in the Federal Register notice. Those are the primary sources worth reading before trusting any secondhand summary, including this one.
The Detail Most Coverage Left Out: FDA Staff Recommended Against All Seven
Before an advisory committee meets, FDA review staff publish briefing documents setting out the agency's own assessment of the substances under discussion. For this meeting, FDA's pre-meeting briefing documents recommended against adding all seven peptides to the list of bulk substances that state-licensed pharmacies can use in compounding, citing gaps in characterization, effectiveness and safety data.
So the committee's favorable votes ran counter to the agency's own written position going into the meeting. That is unusual, and it is genuinely newsworthy. It is also the single strongest reason not to read these votes as a settled outcome. The FDA makes the final call, and its reviewers have already put on record why the submitted data did not persuade them.
How the Committee Voted
| Peptide | Committee outcome | Reported tally |
|---|---|---|
| BPC-157 | Favorable, recommend adding | 8 in favor, 6 against, 1 abstention |
| TB-500 | Favorable, recommend adding | 8 in favor, 6 against, 1 abstention |
| KPV | Favorable, recommend adding | 8 in favor, 6 against, 1 abstention |
| MOTS-c | Favorable, recommend adding | Favorable vote recorded; tally not itemized here |
| Semax | Favorable, recommend adding | Favorable vote recorded; tally not itemized here |
| Epitalon | Favorable, recommend adding | Favorable vote recorded; tally not itemized here |
| Emideltide (DSIP) | Not recommended | Rejected |
The margins matter. On the three peptides with reported tallies, a shift of two votes would have reversed the result. These were not consensus endorsements. They were narrow splits on a panel that had just reviewed a staff assessment recommending rejection.
What Still Has to Happen Before a Final Decision
For any of these peptides to be added to the list of bulk substances that state-licensed pharmacies can use in compounding, the FDA has to complete notice-and-comment rulemaking. In outline, that process runs:
- The FDA weighs the committee's recommendation against its own scientific assessment.
- The agency publishes a proposed rule in the Federal Register.
- A public comment period opens, and interested parties file comments on the record.
- The agency reviews those comments and issues a final rule, which may adopt, modify, or decline the recommendation.
That sequence commonly takes 12 months or more, and the outcome is not predetermined at any step. A favorable advisory vote is an input to stage one. It is not a shortcut past stages two through four.
When this article first ran, the vote by itself had not changed what a compounding pharmacy could prepare. The October 28, 2026 HHS policy is what changed that, and only on a temporary, conditional basis. Rulemaking is still the path to a final answer, and the final rule could include or exclude each peptide.
What This Does and Does Not Mean, Peptide by Peptide
BPC-157. A synthetic peptide sequence studied largely in preclinical models for tissue repair and gut signaling. The committee voted to recommend adding it, and a final FDA decision is pending. Since October 28, 2026 it is covered by the interim HHS policy as a single-ingredient product for subcutaneous, intramuscular, oral or topical use. It is not FDA-approved. For background on the science and the review timeline, see the telos rx BPC-157 patient guide written ahead of this PCAC review, and the accompanying safety and contraindications overview.
TB-500. A thymosin beta-4 related fragment studied preclinically in the context of tissue repair and cell migration. Same picture: a favorable recommendation on a narrow vote and a pending FDA decision. It is covered by the interim HHS policy as a single-ingredient product for subcutaneous or intramuscular injection. Mechanism background is covered in the telos rx TB-500 research overview.
Semax. A short neuropeptide studied primarily in Russian-language literature for effects on cognitive and neurotrophic signaling. Recommended favorably by the committee and pending at the FDA. The interim HHS policy covers it for intranasal use only. See the telos rx Semax research overview.
MOTS-c. A mitochondrial-derived peptide studied in metabolic and mitochondrial signaling research. Recommended favorably and pending at the FDA. The interim HHS policy covers it for subcutaneous or intramuscular injection. See the telos rx MOTS-c research overview.
KPV and epitalon, the other two peptides the committee backed, are also in the HHS policy (KPV for topical and oral use only, epitalon by injection in intermittent courses). DSIP is not. None of these peptides is FDA-approved for any human use. Where they are available at all, it is by prescription only, after review by a US-licensed provider, and approval is never guaranteed.
How to Read Coverage of This Vote
The fastest way to judge whether a source got this story right is to check the verbs.
| Accurate framing | Inaccurate framing |
|---|---|
| An FDA advisory committee voted to recommend adding these peptides | The FDA approved these peptides |
| A final FDA decision is pending and requires rulemaking | These peptides are permanently allowed |
| The votes were narrow, and FDA staff had recommended against | The FDA endorsed these peptides |
| HHS announced a temporary, conditional enforcement discretion policy on October 28, 2026 | These peptides can now be compounded in any form or blend |
| Emideltide (DSIP) was not recommended | Peptides were banned at this meeting |
Any source using the language in the right column is either compressing the story badly or selling something. A recommendation from an advisory committee and a decision from a federal agency are not the same event, and the gap between them is measured in months of rulemaking, not days. The same care applies to the HHS policy: it is interim enforcement discretion with conditions, not a final rule and not FDA approval.
Frequently Asked Questions
Did the FDA approve BPC-157, TB-500, Semax or MOTS-c in July 2026?
No. An FDA advisory committee voted to recommend adding them to the list of bulk substances that state-licensed pharmacies can use in compounding. That is a recommendation, not FDA approval of a drug. The October 28, 2026 HHS policy is not FDA approval either. None of these peptides is FDA-approved for any human use.
What is the Pharmacy Compounding Advisory Committee?
PCAC is a committee of outside experts that advises the FDA on questions related to pharmacy compounding, including which bulk drug substances should be eligible for use in compounding by state-licensed pharmacies. It discusses evidence in public and registers opinions by vote. Its recommendations are advisory and non-binding, and it does not issue regulations.
Did the July 2026 vote change what a pharmacy can compound?
The vote alone did not. What changed things was the October 28, 2026 HHS interim enforcement discretion policy. HHS does not intend to take enforcement action against state-licensed pharmacies or licensed physicians that compound BPC-157, epitalon, KPV, MOTS-c, Semax or TB-500 with a valid prescription, as long as strict conditions are met: FDA-registered suppliers, lot-level testing, single-ingredient products, specific routes and adverse event reporting. It is temporary while FDA completes rulemaking, it is not FDA approval, and HHS can revisit it if safety or quality problems arise.
Why did the committee vote differently from the FDA's own staff?
FDA's pre-meeting briefing documents recommended against adding all seven peptides, citing gaps in characterization, effectiveness and safety data. The committee nonetheless voted favorably on six of them. Advisory committees are convened precisely so that outside experts can reach their own conclusions, and they sometimes diverge from agency reviewers. The divergence is one reason the eventual FDA decision remains genuinely open.
Which peptide was not recommended?
Emideltide, also known as DSIP or delta sleep-inducing peptide, was the one substance of the seven that the committee did not recommend for addition to the list of bulk substances that state-licensed pharmacies can use in compounding. DSIP is also not included in the October 28, 2026 HHS policy.
How long until there is a final answer?
There is no fixed deadline. The FDA must work through the rulemaking process described above, and that commonly takes 12 months or more from the point of an advisory committee recommendation. The interim HHS policy lasts until a final rule addresses each peptide. Anyone offering a specific date, or presenting the outcome as already decided, is speculating.
This article is educational and regulatory in nature and is not medical advice. BPC-157, TB-500, Semax, MOTS-c, KPV, epitalon and emideltide are research peptides and are not FDA-approved for any human use. The July 2026 PCAC vote is an advisory recommendation only, and a final FDA decision is pending. The October 28, 2026 HHS interim enforcement discretion policy covers BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 under strict conditions; it is temporary, revisable and not FDA approval, and it does not cover emideltide (DSIP). Compounded medications are not FDA-approved and are prepared under federal and state compounding regulations. Any prescription requires review by a US-licensed provider, and approval is not guaranteed. Individual results vary. telos rx is LegitScript-certified and operates as an online-first, asynchronous telehealth service.